IP Library Granted Patent US 7,470,827
Granted Patent B2
US 7,470,827 · App. 11/913,803 · Granted Dec 30, 2008

Composition for the vapor phase dehydrohalogenation of 1,1,2-trihaloethane to 1,1-dihaloethylene and methods for preparing and using such composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,470,827
App. No.
11/913,803
Granted
Dec 30, 2008
Kind
B2
Abstract

Described are compositions adapted to catalyze the vapor phase dehydrohalogenation of 1,1,2-trihaloethane to 1,1-dihaloethylene, e.g., 1,1,2-trichloroethane to vinylidene chloride. These materials include activated carbon and at least one benzimidazole-containing material defined herein as including benzimidazole, a derivative thereof, a salt thereof or mixtures thereof. Also described are methods for producing and using these catalytic compositions.

Claims (72)

1. A composition adapted to catalyze the vapor phase dehydrohalogenation of 1,1,2-trihaloethane to 1,1-dihaloethylene comprising activated carbon and at least one benzimidazole-containing material.

2. The composition of claim 1 wherein the activated carbon is chosen from a synthetic activated carbon, activated charcoal, activated kernel carbon, activated birch carbon or mixtures thereof.

3. The composition of claim 2 wherein the activated carbon is a synthetic activated carbon comprising from 1 to 8 weight percent of nitrogen.

4. The composition of claim 1 wherein the activated carbon comprises a specific surface area of from 250 to 2000 meters squared per gram.

5. The composition of claim 1 wherein the activated carbon comprises pores of a size equal to or greater than 2 nanometers.

6. The composition of claim 5 wherein the activated carbon comprises pores of a size from 2 to 50 nanometers.

7. The composition of claim 1 wherein the at least one benzimidazole-containing material comprises benzimidazole, derivatives thereof, salts thereof or mixtures thereof.

8. The composition of claim 1 wherein the at least one benzimidazole-containing material comprises an acidity constant (pKa) of at least 10.0 in acetonitrile.

9. The composition of claim 8 wherein the at least one benzimidazoler-containing material comprises an acidity constant (pKa) of from 10.1 to 18.1 in acetonitrile.

10. The composition of claim 7 wherein the at least one benzimidazole-containing material is represented by at least one of the following graphic formulae, salts thereof or mixtures thereof:

wherein:

(a) R is chosen from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy(C 1 -C 4 )alkyl, C 3 -C 6 cycloalkyl, mono(C 1 -C 6 )alkoxy(C 3 -C 6 )-cycloalkyl, mono(C 1 -C 6 )alkyl(C 3 -C 6 )cycloalkyl, halo(C 3 -C 6 )cycloalkyl, —N(R 4 )R 5 , —(C 1 -C 6 )alkylene-N(R 4 )R 5 or —(C 1 -C 6 )alkylene-oxy-N(R 4 )R 5 , wherein R 4 and R 5 are each independently chosen for each occurrence from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 5 -C 7 cycloalkyl, C 6 -C 20 bicycloalkyl, C 7 -C 20 tricycloalkyl, mono(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, aryl, furanyl, thienyl, C 1 -C 6 alkoxyalkyl, mono-substituted and di-substituted aryl, or R 4 and R 5 together with the nitrogen atom form an unsubstituted, mono-substituted or di-substituted heterocyclic ring chosen from pyridyl, quinolyl, isoquinolyl, indolinyl, morpholino, pyrimidinyl, piperidino, pyrrolidyl, imidazolidyl, imidazolinyl, pyrazolidyl, pyrazolinyl, piperazinyl, pyrryl, C 6 -C 20 heterobicycloalkyl or, C 7 -C 20 heterotricycloalkyl, each of said aryl and heterocyclic ring substituents being chosen from halo, amino, mono(C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkylene, mono(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

(b) R 1 is chosen from:

(i) hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy(C 1 -C 6 )alkyl, C 1 -C 6 alkyl(C 1 -C 6 )alkoxy, aryloxy(C 1 -C 6 )alkyl, aryl(C 1 -C 6 )alkyl, haloaryl(C 1 -C 6 )alkyl, aryl(C 1 -C 6 )alkoxy, haloaryl(C 1 -C 6 )alkoxy, C 3 -C 6 cycloalkyl, mono(C 1 -C 6 )alkoxy(C 3 -C 6 )cycloalkyl, mono(C 1 -C 6 )alkyl(C 3 -C 6 )cycloalkyl, halo(C 3 -C 6 )cycloalkyl, —(C 1 -C 6 )alkylene-N(R 4 )R 5 , —(C 1 -C 6 )alkylene-oxy-N(R 4 )R 5 or —N(R 4 )R 5 ; or

(ii) unsubstituted, mono-, di-, or tri-substituted aryl groups, phenyl or naphthyl, each of said aryl substituents being chosen from —N(R 4 )R 5 , hydroxy, aryl, mono(C 1 -C 6 )alkoxyaryl, di(C 1 -C 6 )alkoxyaryl, mono(C 1 -C 6 )alkylaryl, C 1 -C 6 alkoxy (C 1 -C 6 )alkoxy, di(C 1 -C 6 )alkylaryl, haloaryl, C 3 -C 7 cycloalkylaryl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyloxy, C 3 -C 7 cycloalkyloxy(C 1 -C 6 )alkyl, C 3 -C 7 cycloalkyloxy(C 1 -C 6 )alkoxy, aryl(C 1 -C 6 )alkyl, aryl(C 1 -C 6 )alkoxy, aryloxy, aryloxy(C 1 -C 6 )alkyl, aryloxy(C 1 -C 6 )alkoxy, mono- or di-(C 1 -C 6 )alkylaryl(C 1 -C 6 )alkyl, mono- or di-(C 1 -C 6 )alkoxyaryl(C 1 -C 6 )alkyl, mono- or di-(C 1 -C 6 )alkylaryl(C 1 -C 6 )alkoxy, mono- or di-(C 1 -C 6 )alkoxyaryl(C 1 -C 6 )alkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, mono(C 1 -C 6 )alkoxy(C 1 -C 4 )alkyl, halogen, —SR 3 , or —S(0)R 3 ; wherein R 3 is chosen from —N(R 4 )R 5 , C 1 -C 6 alkyl, phenyl(C 1 -C 3 )alkyl, mono(C 1 -C 6 )alkyl substituted phenyl(C 1 -C 3 )alkyl, mono(C 1 -C 6 )alkoxy substituted phenyl(C 1 -C 3 )alkyl or an unsubstituted, mono- or di-substituted aryl group wherein each of said aryl group substituents of R 3 being independently chosen from —N(R 4 )R 5 , C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

(c) each R 2 is independently chosen for each occurrence from: R or R 1 and n is the integer 0, 1, 2, 3 or 4;

(d) X 1 is chosen from —(CH 2 ) t —; —O—(CH 2 ) t —; or —O—(CH 2 ) t —O—; wherein t is the integer 1, 2, 3, 4, 5 or 6; or the group T represented by the formula:

—Z[(OC 2 H 4 ) a (OC 3 H 6 ) b (OC 4 H 8 ) c ]Z or

—[(OC 2 H 4 ) a (OC 3 H 6 ) b (OC 4 H8) c ]—

wherein —Z is —C(O)— or —CH 2 —, a, b and c are each a number between 0 and 50, and the sum of a, b and c is between 2 and 50; and x and y are each independently chosen for each occurrence from 2, 3 or 4; and

(e) M is chosen from hydroxy, acryloxy, methacryloxy, 2-(acryloxy)ethyl carbamyl, 2-(methacryloxy)ethylcarbamyl, epoxy, vinyl, allyl or tri(C 1 -C 6 )alkoxysilyl.

11. The composition of claim 10 wherein the at least one benzimidazole-containing material is represented by at least one of the following graphic formulae I or III:

wherein:

(a) R is chosen from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halo(C 3 -C 6 )cycloalkyl, —N(R 4 )R 5 , —(C 1 -C 6 )alkylene-N(R 4 )R 5 or —(C 1 -C 6 )alkylene-oxy-N(R 4 )R 5 , wherein R 4 and R 5 are each independently chosen for each occurrence from hydrogen, C 1 -C 6 alkyl, mono(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, aryl, furanyl, thienyl, mono-substituted or di-substituted aryl, or R 4 and R 5 together with the nitrogen atom form an unsubstituted or mono-substituted heterocyclic ring chosen from pyridyl, quinolyl, isoquinolyl, morpholino or piperidino, each of said aryl and heterocyclic ring substituents being chosen from halo, amino, mono(C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkylene, mono(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkylene, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

(b) R 1 is chosen from:

(i) hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, aryloxy(C 1 -C 6 )alkyl, halo(C 3 -C 6 )cycloalkyl, —(C 1 -C 6 )alkylene-N(R 4 )R 5 , —(C 1 -C 6 )alkylene-oxy-N(R 4 )R 5 or —N(R 4 )R 5 ; or

(ii) unsubstituted, mono-, or di-substituted aryl groups, phenyl or naphthyl, each of said aryl substituents being chosen from —N(R 4 )R 5 , aryl, mono(C 1 -C 6 )alkoxyaryl, di(C 1 -C 6 )alkoxyaryl, mono(C 1 -C 6 )alkylaryl, di(C 1 -C 6 )alkylaryl, haloaryl, C 3 -C 7 cycloalkylaryl, aryloxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, halogen, or —SR 3 ; wherein R 3 is chosen from —N(R 4 )R 5 , C 1 -C 6 alkyl, or an unsubstituted, or mono-substituted aryl group wherein each of said aryl group substituents of R 3 being independently chosen from —N(R 4 )R 5 , C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

(c) each R 2 is independently chosen for each occurrence from: R or R 1 and n is the integer 0, 1, 2 or 3;

(d) X 1 is chosen from —(CH 2 ) t —; wherein t is the integer 1, 2, 3, 4, 5 or 6.

12. The composition of claim 11 wherein:

(a) R is chosen from hydrogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, or —N(R 4 )R 5 , wherein R 4 and R 5 are each independently chosen for each occurrence from hydrogen or C 1 -C 3 alkyl or R 4 and R 5 together with the nitrogen atom form an unsubstituted or mono-substituted heterocyclic ring chosen from pyridyl, quinolyl, isoquinolyl, morpholino or piperidino, each of said aryl and heterocyclic ring substituents being chosen from chloro, fluoro, amino, mono(C 1 -C 3 )alkylamino, or di(C 1 -C 3 )alkylamino;

(b) R 1 is chosen from:

(i) hydrogen C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, halo(C 3 -C 6 )cycloalkyl, phenoxy(C 1 -C 3 )alkyl, naphthoxy (C 1 -C 3 )alkyl, —(C 1 -C 3 )alkylene-N(R 4 )R 5 , —(C 1 -C 3 )alkylene-oxy-N(R 4 )R 5 or —N(R 4 )R 5 ; or

(ii) unsubstituted, or mono-substituted aryl groups, phenyl or naphthyl, each of said aryl substituents being chosen from —N(R 4 )R 5 , aryl, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, chloro or fluoro;

(c) each R 2 is independently chosen for each occurrence from: R or R 1 and n is the integer 0,1 or 2; and

(d) X 1 is chosen from —(CH 2 ) t —; wherein t is the integer 1, 2 or 3.

13. The composition of claim 1 wherein the at least one benzimidazole-containing material is chosen from:

a) 2-phenylbenzimidazole;

b) 2-(4-chlorophenyl)benzimidazole;

c) 2-(4-chlorophenyl)-1-methylbenzimidazole;

d) 1-methyl-2-(4-methoxyphenyl)benzimidazole;

e) 1,2,4,5-bis(methylimidazo)benzene;

f) 2-(4-tolyl)benzimidazole;

g) 2-(4-pyridyl)benzimidazole;

h) 2-ethyl-1-methylbenzimidazole;

i) 1-methyl-2-(4-tolyl)benzimidazole;

j) 2-methylbenzimidazole;

k) bis(2-benzimidazolyl)methane;

l) 1,2,4,5-bis(methylimidazo)benzene;

m) benzimidazole;

n) 2-(phenoxymethyl)benzimidazole;

o) 2-(2-naphthoxymethyl)benzimidazole;

p) 2-(4-dimethylaminophenyl)benzimidazole;

q) salts thereof; or

r) mixtures thereof.

14. The composition of claim 1 wherein the composition is adapted to catalyze the vapor phase dehydrohalogenation of 1,1,2-trichloroethane to 1,1-dichloroethylene.

15. A method for dehydrohalogenating 1,1,2-trihaloethane to 1,1-dihaloethylene comprising:

a) obtaining an activated carbon comprising a catalytic amount of at least one benzimidazole-containing material;

b) obtaining a vapor phase of 1,1,2-trihaloethane; and

c) contacting (a) with (b) to form reaction products comprising 1,1-dihaloethylene.

16. The method of claim 15 for dehydrohalogenating 1,1,2-trihaloethane to 1,1-dihaloethylene further comprising:

d) recovering 1,1-dihaloethylene from (c).

17. The method of claim 15 wherein b) comprises a non-reactive diluent.

18. The method of claim 15 wherein the vapor phase of 1,1,2-trihaloethane in b) is maintained at a temperature of from 114° C. to 300° C.

19. The method of claim 15 wherein the contacting of (a) with (b) to form reaction products comprising 1,1-dialoethylene comprises from 0.1 second to 3,600 seconds.

20. The method of claim 15 wherein the method is for the dehydrohalogenation of 1,1,2-trichloroethane to 1,1-dichloroethylene.

21. A method for producing a composition adapted to catalyze the dehydrohalogenation of 1,1,2-trihaloethane to 1,1-dihaloethylene comprising:

a) obtaining an activated carbon; and

b) introducing at least one benzimidazole-containing material into said activated carbon.

22. The method of claim 21 further comprising c) dissolving the at least one benzimidazole-containing material in solvent prior to introducing said benzimidazole-containing material into the activated carbon.

23. The method of claim 22 wherein said solvent in c) is chosen from water, acetone, acetonitrile, ethanol, propanol, methylane chloride, n-methylpyrrolidinones dioxane, chloroform, nitromethane, benzene, toluene, methyl ethyl ketone, methyl isobutyl ketone, isopropyl alcohol, propylene carbonate, 2-methoxyethyl ether, xylene, cyclohexane, 3-methyl cyclohexanone, ethyl acetate, butyl acetate, tetrahydroduran, amyl propionate, methyl propionate, propylene glycol methyl ether, dimethyl sulfoxide, dimethyl formamide, diethylene glycol dibenzoate, dialkyl ethers of ethylene glycol, dimethyl ether, dimethyl ether derivates, or mixtures thereof.

24. The method of claim 21 wherein the method is for producing material adapted to catalyze the dehydrohalogenation of 1,1,2-trichloroethane to 1,1-dichloroethylene.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2016
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: AXIALL CORPORATION; ROYAL MOULDINGS LIMITED; PLASTIC TRENDS, INC.; AXIALL OHIO, INC.; GEORGIA GULF CORPORATION; EXTERIOR PORTFOLIO, LLC
Reel/Frame 039857/0569 →
SUBSTITUTION OF ADMINISTRATIVE AGENT & ASSIGNMENT OF RIGHTS UNDER CREDIT AGREEMENT AND LOAN DOCUMENTS Recorded Sep 16, 2016
From: GENERAL ELECTRIC COMPANY, AS ADMINISTRATIVE AGENT
To: WELLS FARGO CAPITAL FINANCE, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040055/0033 →
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2016
From: WELLS FARGO CAPITAL FINANCE, LLC
To: EAGLE SPINCO, INC.; EAGLE HOLDCO 3 LLC; EAGLE US 2 LLC; EAGLE CONTROLLED 2 OHIO SPINCO, INC.; EAGLE NATRIUM LLC; EAGLE PIPELINE, INC.; PHH MONOMERS L.L.C.; EAGLE CONTROLLED 1 CANADIAN SPINCO, INC.
Reel/Frame 039768/0655 →
SUBSTITUTION OF ADMINISTRATIVE AGENT AS SUCCESSOR BY MERGER Recorded Sep 15, 2016
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: GENERAL ELECTRIC COMPANY, ADMINISTRATIVE AGENT AS SUCCESSOR BY MERGER
Reel/Frame 040053/0855 →
SECURITY AGREEMENT Recorded Mar 3, 2015
From: AXIALL CORPORATION; ROYAL MOULDINGS LIMITED; PLASTIC TRENDS, INC.; GEORGIA GULF CORPORATION; EXTERIOR PORTFOLIO, LLC; AXIALL OHIO, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 035121/0600 →
RELEASE OF SECURITY INTEREST Recorded Mar 2, 2015
From: U.S. BANK NATIONAL ASSOCIATION
To: AXIALL OHIO, INC.
Reel/Frame 035115/0559 →
CHANGE OF NAME Recorded Jul 10, 2013
From: EAGLE CONTROLLED 2 OHIO SPINCO, INC.
To: AXIALL OHIO, INC.
Reel/Frame 030764/0631 →
SECURITY AGREEMENT Recorded Feb 11, 2013
From: EAGLE CONTROLLED 2 OHIO SPINCO, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 029787/0794 →
PATENT SECURITY AGREEMENT Recorded Jan 29, 2013
From: EAGLE SPINCO, INC.; EAGLE HOLDCO 3 LLC; EAGLE US 2 LLC; EAGLE CONTROLLED 2 OHIO SPINCO, INC.; EAGLE NATRIUM LLC; PHH MONOMERS, L.L.C.; EAGLE PIPELINE, INC.; EAGLE CONTROLLED 1 CANADIAN SPINCO, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 029717/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2013
From: PPG INDUSTRIES OHIO, INC.
To: EAGLE CONTROLLED 2 OHIO SPINCO, INC.
Reel/Frame 029702/0982 →